Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 289 results for "zydus group cadila healthcare"

Cadila Healthcare launches Hepatitis C drug SoviHep
Odisha Samaya

Cadila Healthcare launches Hepatitis C drug SoviHep

New Delhi: Cadila Healthcare or Zydus Cadila has announced to launch an oral therapy SoviHep for the treatment of Hepatitis C. It is the Ahmedabad-based pharma major Cadila Healthcare has launched Hepatitis C drug and would be marketed by the ... Odisha Samaya, 1 week ago
[x]  

5 images for zydus group cadila healthcare

India Infoline, 1 week ago
Money Control, 1 week ago
Odisha Samaya, 1 week ago
India Infoline, 11 hours ago
Business Standard India, 1 month ago
Business Standard India

Zydus Cadila to make presentation on Saroglitazar at Keystone Symposia

AHMEDABAD: Zydus Cadila group will be making an oral presentation on Saroglitazar, a novel compound under development for treatment in Non-alcoholic Steatohepatitis (NASH), at the Keystone Symposium on Liver Metabolism and Non-alcoholic Fatty Liver ...
 Times of India1 month ago Cadila Healthcare intimates presentation of Saroglitazar for treatment of NASH  Business Standard India1 month ago Zydus to present data from Saroglitazar to treat NASH at Keystone Symposium  PharmaBiz1 month ago Zydus to make presentation on Saroglitazar at Keystone Symposium  Smart Investor1 month ago

Buy Cadila Healthcare; target Rs 1727: Firstcall Research

Firstcall Research's report on Cadila Healthcare For the 3rd quarter ended Dec 31st, 2014, Zydus Cadila reported Net sales of Rs 21894.60 mn, up by 16.98% from Rs. 18716.90 mn in the corresponding quarter of the previous year on a consolidated ...
 Moneycontrol.com1 month ago Zydus Cadila Net Profit up by 52% in Q3  FiercePharma1 month ago

Cadila Healthcare gains on inking non-exclusive licensing pact with Gilead Sciences

Cadila Healthcare is currently trading at Rs. 1592.80, up by 6.85 points or 0.43% from its previous closing of Rs. 1585.95 on the BSE. The scrip opened at Rs. 1590.00 and has touched a high and low of Rs. 1619.55 and Rs. 1577.00 respectively. So ...
 Arihant Capital1 week ago Zydus Cadila, Gilead Sciences ink non-exclusive licensing pact  Indian-Commodity1 week ago Cadila Healthcare advances despite recalling cough treatment drug in US  Arihant Capital2 months ago

Cadila Healthcare net jumps by 52% in Q3 to Rs. 282 cr

Cadila Healthcare, a Rs. 7,200 crore pharma major from Ahmedabad, has posted impressive financial performance during the third quarter ended December 2014 and its consolidated net profit went up sharply by 51.6 per cent to Rs. 282 crore from Rs. 186 ...
 PharmaBiz1 month ago Cadila Healthcare bucks trend on strong Q3 earnings  Capital Market1 month ago

Cadila recalls 19,536 bottles of cough treatment drug in US

dia | New Delhi January 8, 2015 Last Updated at 18:45 IST Drug firm Cadila Healthcare is voluntarily recalling 19,536 bottles of benzonatate capsules, used to treat coughs, in the US due to "wet and/or leaking capsules". According to a notification ...
 Business Standard India2 months ago Cadila Healthcare recalls 19,536 bottles of cough treatment drug in US  Economic Times2 months ago
[x]  

Zydus begins Phase - III study of Saroglitazar in NASH, a liver disease caused by obesity, diabetes and lipid disorders

Details Category: Small Molecules Published on Sunday, 11 January 2015 21:06 Hits: 45 January 9, 2015 I The Zydus group announced the initiation of Phase III clinical trials to study its effect in adult nonalcoholic steatohepatitis (NASH) ...
 PipelineReview2 months ago
India Infoline

Cadila spurts 4% at opening bell

News Top News Top Story India Infoline News Service | Mumbai | March 18, 2015 09:36 IST New drug launch by Zydus group boosts sentiment at the counter. Cadila Healthcare spurted ...
 India Infoline1 week ago
Business Standard India

Capital International in talks to buy stake in Mankind Pharma

Secondary private equity transactions seem to be on the rise in India's healthcare space. Capital International, a global private equity (PE) fund, is learnt to be in talks to acquire a 11 per cent stake in Delhi-based Mankind Pharma for Rs ...
 Business Standard India1 month ago
Financial Express

The Gujarat Model: Is it the way forward?

Gujarat has done very well in some sectors but with its health indicators still lagging behind, will it be the blueprint for the rest of India? By Raelene Kambli Sickle Cell Anemia Control Programme Gujarat's model of development has been ...
 Financial Express2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - zydus group cadila healthcare
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less